The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 4, 2008, Pages 299-307

  Lavergne, Sidonie Nelly ^a   Park, Brian Kevin ^a   Naisbitt, Dean John ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cytotoxicity; Danger signal; Drug metabolites; Drug metabolizing enzymes; Drug?protein adducts; Hapten theory; Oxidative stress; Pharmacogenomics; Pi concept; T cells

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ABACAVIR; ALLOPURINOL; AMODIAQUINE; ANTIBODY; CARBAMAZEPINE; CELECOXIB; CLINDAMYCIN; CLOZAPINE; DAPSONE; DEETHYLLIDOCAINE; DICLOFENAC; DIFLUNISAL; DRUG METABOLITE; DRUG METABOLIZING ENZYME; GLYCINE XYLIDIDE; HAPTEN; HYDROXYLAMINE; LAMOTRIGINE; LIDOCAINE; NITROSOSULFAMETHOXAZOLE; PHENYLENEDIAMINE; PHENYTOIN; SULFAMETHOXAZOLE; UNCLASSIFIED DRUG; XIMELAGATRAN; DRUG; REACTIVE OXYGEN METABOLITE; T LYMPHOCYTE RECEPTOR;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME POLYMORPHISM; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IMMUNOTOXICITY; INNATE IMMUNITY; LIVER METABOLISM; LIVER TOXICITY; LYMPHOCYTE CLONE; NONHUMAN; OXIDATIVE STRESS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SKIN; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ANIMAL; BIOTRANSFORMATION; CHEMISTRY; CYTOLOGY; DRUG EFFECT; DRUG HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHARMACOGENETICS;

ANIMALS; BIOTRANSFORMATION; DRUG HYPERSENSITIVITY; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; OXIDATIVE STRESS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; REACTIVE OXYGEN SPECIES; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 66149086597     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283079c64     Document Type: Review

References (102)

1. Raksha MP, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol 2008; 74:80.
2. Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 2007; 64:1840-1843.
3. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23:483-507.
4. Park BK, Naisbitt DJ, Gordon SF, et al. Metabolic activation in drug allergies. Toxicology 2001; 158:11-23.
5. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis: potential role in idiosyncratic drug reactions. Toxicology 2002; 181- 182:55-63.
6. Seguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003; 3:235-242.
7. Pichler WJ. Modes of presentation of chemical neoantigens to the immune system. Toxicology 2002; 181-182:49-54.
8. Pichler WJ, Beeler A, Keller M, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int 2006; 55:17-25.
9. Cribb AE, Spielberg SP. Hepatic microsomal metabolism of sulfamethox-azole to the hydroxylamine. Drug Metab Dispos 1990; 18:784-787.
10. Tam YK, Ke J, Coutts RT, et al. Quantification of three lidocaine metabolites and their conjugates. Pharm Res 1990; 7:504-507.
11. Pearce RE, Uetrecht JP, Leeder JS. Pathways of carbamazepine bioactiva-tion in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 2005; 33:1819-1826.
12. Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos 2002; 30:1170-1179.
13. Lu W, Uetrecht JP. Possible bioactivation pathways of lamotrigine. Drug Metab Dispos 2007; 35:1050-1056.
14. Maggs JL, Naisbitt DJ,Tettey JN, et al.. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000; 13:1075-1081.
15. Chakraborty AK. Lighting up TCR takes advantage of serial triggering. Nat Immunol 2002; 3:895-896.
16. Labrecque N, Whitfield LS, Obst R, et al. How much TCR does a T cell need? Immunity 2001; 15:71 -82.
17. Schodin BA, Tsomides TJ, Kranz DM. Correlation between the number of T cell receptors required for T cell activation and TCR-ligand affinity. Immunity 1996; 5:137-146.
18. Wei X, Tromberg BJ, Cahalan MD. Mapping the sensitivity of T cells with an optical trap: polarity and minimal number of receptors for Ca(2+) signalling. Proc Natl Acad Sci USA 1999; 96:8471 -8476.
19. Ju C, Uetrecht JP. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J Pharmacol Exp Ther 1999; 288:51 -56.
20. Winter HR, Trapnell CB, Slattery JT, et al. The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clin Pharmacol Ther 2004; 76:313-322.
21. Baron JM, Holler D, Schiffer R, et al. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol 2001; 116:541 -548.
22. Oesch F, Fabian E, Oesch-Bartlomowicz B, et al. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 2007; 39:659-698.
23. Saeki M, Saito Y, Nagano M, et al. mRNA expression of multiple cytochrome p450 isozymes in four types of cultured skin cells. Int Arch Allergy Immunol 2002; 127:333-336.
24. Bergstrom MA, Ott H, Carlsson A, et al. A skin-like cytochrome P450 cocktail activates prohaptens to contact allergenic metabolites. J Invest Dermatol 2007; 127:1145-1153.
25. Bhaiya P, Roychowdhury S, Vyas PM, et al. Bioactivation, protein haptena-tion, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts. Toxicol Appl Pharmacol 2006; 215:158-167.
26. Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM. P450 2C18 catalyzes the metabolic bioactivation of phenytoin. Chem Res Toxicol 2005; 18:1868-1875.
27. Roychowdhury S, Cram AE, Aly A, Svensson CK. Detection of haptenated proteins in organotypic human skin explant cultures exposed to dapsone. Drug Metab Dispos 2007; 35:1463-1465.
28. Vyas PM, Roychowdhury S, Koukouritaki SB, et al.. Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: II. Expression and role of flavin-containing monooxygenases and peroxidases. J Pharmacol Exp Ther 2006; 319:497-505.
29. Wolkenstein P, Tan C, Lecoeur S, et al. Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem Biol Interact 1998; 113:39-50.
30. Sanderson JP, Naisbitt DJ, Farrell J, et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol 2007; 178:5533-5542.
31. Sieben S, Baron JM, Blomeke B, Merk HF. Multiple cytochrome P450-isoenzymes mRNA are expressed in dendritic cells. Int Arch Allergy Immunol 1999; 118:358-361.
32. Siest G, Jeannesson E, Marteau JB, et al. Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 2008; 36:182-189.
33. Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxi-city. Clin Liver Dis 2007; 11:563-575; vi-vii.
34. Gruchalla RS, Pesenko RD, Do TT, Skiest DJ. Sulfonamide-induced reactions in desensitized patients with AIDS: the role of covalent protein haptenation by sulfamethoxazole. J Allergy Clin Immunol 1998; 101:371 -378.
35. Lavergne SN, Danhof RS, Volkman EM, Trepanier LA. Association of drug-serum protein adducts and antidrug antibodies in dogs with sulphonamide hypersensitivity: a naturally occurring model of idiosyncratic drug toxicity. Clin Exp Allergy 2006; 36:907-915.
36. Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994; 94:1017-1024.
37. Worrall S, Dickinson RG. Rat serum albumin modified by diflunisal acyl glucuronide is immunogenic in rats. Life Sci 1995; 56:1921 -1930.
38. Cheng L, Stewart BJ, You Q, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific t cell responses in vivo. Mol Pharmacol 2008; 73:1769-1775.
39. Carey MA, van Pelt FN. Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 2005; 216:41 -48.
40. Zhou S, Chan E, Duan W, et al. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 2005; 37:41 -213.
41. Naisbitt D, Farrell J, Gordon S, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002; 62:628-637.
42. Naisbitt DJ, Hough SJ, Gill HJ, et al. Cellular disposition of sulphamethox-azole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999; 126:1393-1407.
43. Lavergne SN, Kurian JR, Bajad SU, et al. Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso. Toxicology 2006; 222:25-36.
44. Carr A, Tindall B, Penny R, Cooper DA. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 1993; 94:21 -25.
45. Rieder MJ, Krause R, Bird IA. Time-course of toxicity of reactive sulfonamide metabolites. Toxicology 1995; 95:141-146.
46. Valentine CR, Valentine JL, Seng J, et al. The use of transgenic cell lines for evaluating toxic metabolites of carbamazepine. Cell Biol Toxicol 1996; 12:155-165.
47. Naisbitt DJ, Williams DP, O'Neill PM, et al. Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs. Chem Res Toxicol 1998; 11:1586-1595.
48. Williams DP, Pirmohamed M, Naisbitt DJ, et al. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000; 58:207-216.
49. Wijsman JA, Dekaban GA, Rieder MJ. Differential toxicity of reactive metabolites of clindamycin and sulfonamides in HIV-infected cells: influence of HIV infection on clindamycin toxicity in vitro. J Clin Pharmacol 2005; 45:346-351.
50. Bort R, Ponsoda X, Jover R, et al. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 1999; 288:65-72.
51. Chang YS, Tseng SY, Tseng SH, Wu CL. Cytotoxicity of lidocaine or bupivacaine on corneal endothelial cells in a rabbit model. Cornea 2006; 25:590-596.
52. Nishimura Y, Kanada A, Yamaguchi JY, et al. Cytometric analysis of lidocaine-induced cytotoxicity: a model experiment using rat thymocytes. Toxicology 2006; 218:48-57.
53. Chang JK, Li CJ, Wu SC, et al. Effects of anti-inflammatory drugs on proliferation, cytotoxicity and osteogenesis in bone marrow mesenchymal stem cells. Biochem Pharmacol 2007; 74:1371-1382.
54. Hasinoff BB, Patel D, Wu X. The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Cardiovasc Toxicol 2007; 7:19-27.
55. BavdekarSB, Muranjan MN,Gogtay NJ, et al. Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment. Ann Pharmacother 2004; 38:1648-1650.
56. Neuman MG, Malkiewicz IM, Phillips EJ, et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit 2002; 24:728-736.
57. Tabatabaei AR, Thies RL, Farrell K, Abbott FS. A rapid in vitro assay for evaluation of metabolism-dependent cytotoxicity of antiepileptic drugs on isolated human lymphocytes. Fundam Appl Toxicol 1997; 37:181 -189.
58. Reilly TP, MacArthur RD, Farrough MJ, et al. Is hydroxylamine-induced cytotoxicity a valid marker for hypersensitivity reactions to sulfamethoxazole in human immunodeficiency virus-infected individuals? J Pharmacol Exp Ther 1999; 291:1356-1364.
59. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425:516-521.
60. Aycicek A, Iscan A. The effects of carbamazepine, valproic acid and phenobarbital on the oxidative and antioxidative balance in epileptic children. Eur Neurol 2007; 57:65-69.
61. Vyas PM, Roychowdhury S, Woster PM, Svensson CK. Reactive oxygen species generation and its role in the differential cytotoxicity of the arylhy-droxylamine metabolites of sulfamethoxazole and dapsone in normal human epidermal keratinocytes. Biochem Pharmacol 2005; 70:275-286.
62. Mizuashi M, Ohtani T, Nakagawa S, Aiba S. Redox imbalance induced by contact sensitizers triggers the maturation of dendritic cells. J Invest Dermatol 2005; 124:579-586.
63. Rutault K, Alderman C, Chain BM, Katz DR. Reactive oxygen species activate human peripheral blood dendritic cells. Free Radic Biol Med 1999; 26:232-238.
64. Frossi B, De Carli M, Piemonte M, Pucillo C. Oxidative microenvironment exerts an opposite regulatory effect on cytokine production by Th1 and Th2 cells. Mol Immunol 2008; 45:58-64.
65. Kurien BT, Hensley K, Bachmann M, Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 2006; 41:549-556.
66. Leeder JS, Dosch HM, Spielberg SP. Cellular toxicity of sulfamethoxazole reactive metabolites-I. Inhibition of intracellular esterase activity prior to cell death. Biochem Pharmacol 1991; 41:567-574.
67. Loser K, Beissert S. Dendritic cells and T cells in the regulation of cutaneous immunity. Adv Dermatol 2007; 23:307-333.
68. Novak N, BieberT. 2. Dendritic cells as regulators of immunity and tolerance. J Allergy Clin Immunol 2008; 121:S370-S374; quiz S413.
69. Aeby P, WyssC, BeckH, et al.. Characterization of the sensitizing potential of chemicals by in vitro analysis of dendritic cell activation and skin penetration. J Invest Dermatol 2004; 122:1154-1164.
70. Coulter EM, Farrell J, Mathews KL, et al. Activation of human dendritic cells by p-phenylenediamine. J Pharmacol Exp Ther 2007; 320:885-892.
71. Toebak MJ, Moed H, von Blomberg MB, et al. Intrinsic characteristics of contact and respiratory allergens influence production of polarizing cytokines by dendritic cells. Contact Dermatitis 2006; 55:238-245.
72. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol 2006; 118:949-956.
73. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101:4180-4185.
74. Martin AM, Almeida CA, Cameron P, et al. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 2007; 21:1233-1244.
75. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59:809-820.
76. Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111:1393 - 1403.
77. Sachs B, Erdmann S, Al-Masaoudi T, Merk HF. In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol 2001; 144:316-320.
78. Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ cells from allergic individuals. J Immunol 2000; 164:6647-6654.
79. Tsuge I, Okumura A, Kondo Y, et al. Allergen-specific T-cell response in patients with phenytoin hypersensitivity; simultaneous analysis of proliferation and cytokine production by carboxyfluorescein succinimidyl ester (CFSE) dilution assay. Allergol Int 2007; 56:149-155.
80. Farrell J, Naisbitt DJ, Drummond NS, et al. Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther 2003; 306:229-237.
81. Naisbitt DJ, Sanderson LS, Meng X, et al. Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol Lett 2007; 168:45-50.
82. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004; 123:850-855.
83. Wu Y, Sanderson JP, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006; 118:233-241.
84. Depta JP, Altznauer F, Gamerdinger K, et al. Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J Allergy Clin Immunol 2004; 113:519-527.
85. Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabetaT cell clones. J Clin Invest 1997; 100:136-141.
86. Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998; 102:1591 -1598.
87. Gamerdinger K, Moulon C, Karp DR, et al. A new type of met al. recognition by human T cells: contact residues for peptide-independent bridging of T cell receptor and major histocompatibility complex by nickel. J Exp Med 2003; 197:1345-1353.
88. Cribb AE, Pohl LR, Spielberg SP, Leeder JS. Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum proteins. J Pharmacol Exp Ther 1997; 282:1064-1072.
89. Lavergne SN, Drescher NJ, Trepanier LA. Antimyeloperoxidase and anti-cathepsin G antibodies in sulphonamide hypersensitivity. Clin Exp Allergy 2008; 38:199-207.
90. Sachs UJ, Santoso S, Roder L, et al. Diclofenac-induced antibodies against red blood cells are heterogeneous and recognize different epitopes. Transfusion 2004; 44:1226-1230.
91. Salama A, Gottsche B, Mueller-Eckhardt C. Autoantibodies and drug-or metabolite-dependent antibodies in patients with diclofenac-induced immune haemolysis. Br J Haematol 1991; 77:546-549.
92. Nakatsu K, Scully K. Drug-specific antibodies in human serum? Res Commun Chem Pathol Pharmacol 1980; 27:203-206.
93. Igarashi M, Bando Y, Shimanuki K, et al. Immunosuppressive factors detected during convalescence in a patient with severe serum sickness induced by carbamazepine. Int Arch Allergy Immunol 1993; 100:378-381.
94. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol 1992; 33:183-186.
95. Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994; 125:805-811.
96. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7:813-818.
97. Man CB, Kwan P, Baum L, et al. Association between HLA-B* 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015-1018.
98. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
99. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
100. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immuno-pathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8:186-195.
101. Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000; 10:705-713.
102. Kurian JR, Longlais BJ, Trepanier LA. Discovery and characterization of a cytochrome b5 variant in humans with impaired hydroxylamine reduction capacity. Pharmacogenet Genomics 2007; 17:597-603.